These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2445297)

  • 1. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug.
    Schallreuter KU; Pittelkow MR
    Arch Dermatol; 1987 Nov; 123(11):1494-8. PubMed ID: 2445297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of the 'bioassay' for thioredoxin-reductase activity.
    Fuchs J
    Arch Dermatol; 1988 Jun; 124(6):849-51. PubMed ID: 3377515
    [No Abstract]   [Full Text] [Related]  

  • 3. Calmodulin inhibition by anthralin? Investigations in vitro and in vivo.
    Wollina U; Klinger R; Wetzker R; Knopf B
    Dermatologica; 1989; 179(2):61-3. PubMed ID: 2529149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of anthralin in skin during treatment.
    Juhlin L; Schroot B
    Acta Derm Venereol Suppl (Stockh); 1985; 120():27-9. PubMed ID: 3869415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy.
    Wollina U; Schmidt WD; Koch A; Scheibe A; Erfurth F; Fassler D
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1409-13. PubMed ID: 19508501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis.
    Monk BE; Hehir ME; Clement MI; Pembroke AC; du Vivier A
    Arch Dermatol; 1988 Apr; 124(4):548-50. PubMed ID: 3355198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of calcium in the regulation of free radical reduction by thioredoxin reductase at the surface of the skin.
    Schallreuter KU; Pittelkow MR; Gleason FK; Wood JM
    J Inorg Biochem; 1986; 28(2-3):227-38. PubMed ID: 2433392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells.
    Schallreuter KU; Wood JM
    Cancer Lett; 1987 Sep; 36(3):297-305. PubMed ID: 3652030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes.
    Holstein J; Fehrenbacher B; Brück J; Müller-Hermelink E; Schäfer I; Carevic M; Schittek B; Schaller M; Ghoreschi K; Eberle FC
    J Dermatol Sci; 2017 Sep; 87(3):236-245. PubMed ID: 28673488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of coal tar on cignolin erythema--1 hour treatment of psoriasis with high-dose cignolin with and without tar].
    Schauder S; Mahrle G
    Z Hautkr; 1985 Jun; 60(11):875-83. PubMed ID: 3160177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthralin minute entire skin treatment. A new outpatient therapy for psoriasis.
    Schwarz T; Gschnait F
    Arch Dermatol; 1985 Dec; 121(12):1512-5. PubMed ID: 4062332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal calmodulin levels in psoriasis before & after therapy.
    Kaur I; Kaur S; Vaishnavi C; Ganguly NK; Garg J; Kohli M
    Indian J Med Res; 1991 Apr; 94():130-3. PubMed ID: 1879887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of an anthralin-containing hydrocolloid dressing in psoriasis vulgaris].
    Bunse T; Merk H
    Z Hautkr; 1990 Aug; 65(8):730-2. PubMed ID: 2284832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthralin: how does it act and are there more favourable derivatives?
    Mahrle G; Bonnekoh B; Wevers A; Hegemann L
    Acta Derm Venereol Suppl (Stockh); 1994; 186():83-4. PubMed ID: 8073848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin.
    Paramsothy Y; Lawrence CM
    Br J Dermatol; 1987 Apr; 116(4):517-9. PubMed ID: 3580286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short contact anthralin therapy of psoriasis with and without UV-irradiation and maintenance schedule to prevent relapses.
    Brun P; Juhlin L; Schalla W
    Acta Derm Venereol; 1984; 64(2):174-7. PubMed ID: 6203312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of dithranol therapy on clinical status and serum calcitonin concentrations in patients with common psoriasis].
    Bendkowski W; Hadas E; Swietochowska E; Wielkoszyński T; Ostrowska Z; Szapska B
    Pol Merkur Lekarski; 2002 Dec; 13(78):481-3. PubMed ID: 12666446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin polyamine levels in psoriasis: the effect of dithranol therapy.
    Bohlen P; Grove J; Beya MF; Koch-Weser J; Henry MH; Grosshans E
    Eur J Clin Invest; 1978 Aug; 8(4):215-8. PubMed ID: 100325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-contact anthralin therapy for psoriasis using an aqueous cream formulation.
    Kingston TP; Lowe NJ; Whitefield M; Warin AP; Freeman K
    Cutis; 1987 Feb; 39(2):155-7. PubMed ID: 3829723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.